STING1 and neoplasm: Peritumoural administration of clodronate was found to effectively deplete TAMs without affecting the tumour growth (Figure S23A–D), whereas H151 effectively reversed the antitumour activity of MSA2, a well‐documented STING agonist (Pan et al.